<DOC>
	<DOCNO>NCT01289054</DOCNO>
	<brief_summary>This voluntary , international , primarily prospective , observational , exposure-registry follow-up study woman receive Imatinib Nilotinib pregnancy within six month prior pregnancy .</brief_summary>
	<brief_title>A Global Imatinib Nilotinib Pregnancy Exposure Registry</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Provide sufficient evidence confirm exposure occur pregnancy within 6 month prior exposure . Be least 18 year age Reside country support Registry Cases meet eligibility criterion deem ineligible , include paternal exposure Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Female</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Hematologic Pregnancy</keyword>
	<keyword>Complications</keyword>
	<keyword>Registry</keyword>
	<keyword>Pregnant Registry</keyword>
	<keyword>CML</keyword>
	<keyword>GIST</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Tasigna</keyword>
	<keyword>Glivec</keyword>
	<keyword>Pregnancy Exposure</keyword>
</DOC>